Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | NPR3 | P17342 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810319 | 0.87 | NPR3 (0.39) | EPHX2NPR3EPHX1AAK1GAA | |
| SCHEMBL7433429 | 0.82 | ALDH1A1 (0.40) | EPHX2NPR3EPHX1GAATHRB | |
| SCHEMBL8442372 | 0.80 | SLC6A3 (0.36) | — | |
| SCHEMBL5532288 | 0.79 | CTSK (0.41) | EPHX2CA12CA2CA14EPHX1 | |
| SCHEMBL9556111 | 0.78 | EPHX1 (0.42) | NPR3EPHX1AAK1GAACACNA1B | |
| SCHEMBL5527340 | 0.78 | CTSK (0.40) | EPHX2CA12CA2CA14EPHX1 | |
| SCHEMBL1163035 | 0.74 | MMP13 (0.35) | AAK1GAA | |
| SCHEMBL7424499 | 0.73 | CA12 (0.44) | CA12CA2CA14 | |
| SCHEMBL10566189 | 0.73 | EPHX2 (0.53) | EPHX2CA12CA2EPHX1 | |
| SCHEMBL24103813 | 0.71 | AAK1 (0.49) | CA12CA2CA14EPHX1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-2007788-A2 | HCV INHIBITORS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| WO-2007121125-A2 | HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | EPHX2 2031/4885NPR3 4149/4885CA12 2033/4885 |
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | EPHX2 1389/4885NPR3 2245/4885CA12 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.